Demographics & Therapeutic Focus

ORGANIZATION

Just under half of the survey respondents are from biopharmaceutical and pharmaceutical companies, while a quarter work in academic institutions.

JOB FUNCTION

Over a third of respondents work in VP, head or director roles within their companies. Another third of the respondents are scientists and researchers within their organizations.

REGION

The majority of respondents in the survey are based in North America, while 40% are based in Europe and Asia.

THERAPEUTIC TYPE

89% of the respondents said they are working with monoclonal antibody therapeutics.

Protein therapeutics and bispecifics are the next most common forms of therapeutic, both worked on by the companies of over half of respondents.

THERAPEUTIC AREA

Immunotherapy is still the top target for antibody therapeutics. Outside of cancer, auto-immune diseases (54%) and infectious diseases (45%) are still the next most common therapeutic areas in the sector.

Neurodegenerative conditions have become more common targets (26%) since our industry surveys in 2020 (16%) and 2019 (14%).